The Long-Term Effects of Beta Receptor Agonist Therapy in Relation to Morbidity and Mortality

2020 ◽  
pp. 201-222
Author(s):  
Colin S. Wong ◽  
Anne E. Tattersfield
Keyword(s):  
Receptor Agonist ◽  
Morbidity And Mortality ◽  
Long Term Effects ◽  
Agonist Therapy ◽  
Beta Receptor

Long-term cannabinoid type 2 receptor agonist therapy decreases bacterial translocation in rats with cirrhosis and ascites

2014 ◽  
Vol 61 (5) ◽  
pp. 1004-1013 ◽  
Author(s):  
Ying-Ying Yang ◽  
Shie-Liang Hsieh ◽  
Pei-Chang Lee ◽  
Yi-Chen Yeh ◽  
Kuei-Chuan Lee ◽  
...  
Keyword(s):  
Bacterial Translocation ◽  
Receptor Agonist ◽  
Agonist Therapy

The Anatomy of Loneliness

2003 ◽  
Vol 12 (3) ◽  
pp. 71-74 ◽  
Author(s):  
John T. Cacioppo ◽  
Louise C. Hawkley ◽  
Gary G. Berntson
Keyword(s):  
Risk Factor ◽  
Morbidity And Mortality ◽  
Long Term Effects ◽  
Short Term

Loneliness is a potent but little understood risk factor for broad-based morbidity and mortality. We review five social neurobehavioral mechanisms that may account for this association. The evidence suggests that different mechanisms explain short-term and long-term effects, and that the long-term effects operate through multiple pathways. Implications for the design of interventions are discussed.

Long-Term Effects of High-Dose Chemotherapy and Radiation for Relapsed and Refractory Hodgkin's Lymphoma

2008 ◽  
Vol 26 (32) ◽  
pp. 5240-5247 ◽  
Author(s):  
Karyn A. Goodman ◽  
Elyn Riedel ◽  
Victoria Serrano ◽  
Subhash Gulati ◽  
Craig H. Moskowitz ◽  
...  
Keyword(s):  
General Population ◽  
Hodgkin’S Lymphoma ◽  
High Dose Chemotherapy ◽  
Morbidity And Mortality ◽  
Hodgkin's Lymphoma ◽  
High Dose ◽  
Long Term Effects ◽  
Stem Cell Rescue ◽  
Late Morbidity

Purpose To evaluate the risk of late morbidity and mortality, and to assess long-term health-related quality of life (QOL) among patients with relapsed/refractory Hodgkin's lymphoma (HL) after high-dose chemoradiotherapy (HDT) and autologous stem-cell rescue (ASCR). Patients and Methods From 1985 to 1998, 218 patients with HL were treated on HDT with ASCR salvage protocols. Of these 218, 153 (70%) who survived ≥ 2 years after ASCR were evaluated for late morbidity and mortality from causes other than HL. QOL information was obtained through self-administered questionnaires. Risk ratios (RR) were calculated to compare observed second malignancy (SM) rates in this cohort with expected SM rates from the Surveillance Epidemiology and End Results (SEER) registry. Results Median follow-up after ASCR was 11.5 years. Among 153 patients, there were 53 deaths; 33 from HL and 20 from other causes. Thirteen deaths were caused by SM, with median time from ASCR to SM diagnosis of 9 years (range, 3 to 18 years). The RR of SM was 6.5 (95% CI, 3.6 to 10.7) when compared with the general population, but 2.4 (95% CI, 1.4 to 4.05) when compared with patients with HL. Global QOL of ASCR survivors was comparable with the general population, but for specific domains, respondents’ scores indicated reduced functioning and worse symptoms. Conclusion HL accounts for most deaths among patients surviving HDT and ASCR. Survivors of ASCR had an elevated risk of SM compared with the cancer risk in the general population, but when compared with patients with HL in SEER, the risk was less pronounced.

Corrigendum to “Long-term cannabinoid type 2 receptor agonist therapy decreases bacterial translocation in rats with cirrhosis and ascites” [J Hepatol 2014;61:1004–1013]

2015 ◽  
Vol 62 (5) ◽  
pp. 1219-1220
Author(s):  
Ying-Ying Yang ◽  
Shie-Liang Hsieh ◽  
Pei-Chang Lee ◽  
Yi-Chen Yeh ◽  
Kuei-Chuan Lee ◽  
...  
Keyword(s):  
Bacterial Translocation ◽  
Receptor Agonist ◽  
Agonist Therapy
Sign in / Sign up

Export Citation Format

Share Document